Peptide · Vial
BPC 157
$8910mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
EternaGen / Research use onlyPeptide · Research use only
TB 500
$99CAD
A short peptide fragment related to thymosin beta 4 and explored in early tissue-repair research.
Available to approved purchasers
Select strength
1
Documentation review pending Fulfilled in Canada Research use only
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
TB 500, clearly explained.
A short peptide fragment related to thymosin beta 4 and explored in early tissue-repair research.
Overview
TB-500 usually refers to a small fragment of the much larger thymosin beta 4 peptide. Studies of the full peptide—especially topical eye studies—cannot be treated as proof for this fragment or another delivery method.
TB-500 commonly refers to the LKKTETQ fragment associated with thymosin beta 4. Full-length thymosin beta 4 is a 43-amino-acid peptide; the fragment and parent peptide must not be treated as the same molecular entity.- Format
- Vial
- Available strengths
- 10mg
- Documentation
- Source review pending
Research at a glanceFragment-specific human evidence absent; full-length thymosin beta 4 evidence is not interchangeable
Reviewed 23 July 2026View research context Specifications
Product details
- Storage and handling
- Consult the batch record for verified handling and storage conditions.
Batch documentationSource review pending
Not yet publishedSupplier-origin documentation will be published only after EternaGen verifies the source and record details.
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Actin and cell migration
Laboratory research on thymosin beta 4 examines actin sequestration, cell movement and tissue-response pathways.
Evidence so far: Mechanistic evidenceQuestion 02
Topical ophthalmic research
A phase 2 dry-eye study tested full-length thymosin beta 4 solution and did not meet its two primary endpoints.
Evidence so far: Formulation-specific human trialQuestion 03
TB-500 fragment
FDA reports no identified human exposure data for drug products containing the LKKTETQ fragment.
Evidence so far: Direct human evidence gapProposed mechanism
How researchers are investigating the mechanism.
Thymosin beta 4 binds actin and has been studied in cell migration and repair-related pathways. Even where the parent peptide shows biological activity, molecular identity, formulation and route determine whether a study is relevant to TB-500.
Evidence gaps
What remains unknown?
- Human pharmacology and safety of the TB-500 fragment are not established.
- Product naming can obscure whether the tested material is full-length thymosin beta 4 or a fragment.
- Route, formulation and purity data cannot substitute for molecularly matched clinical evidence.
Primary sources
Check the original sources.
- Primary full-length peptide studySosne and Ousler. Topical thymosin beta 4 phase 2 study. Clin Ophthalmol. 2015. PMID 26056426.
- Fragment-specific safety reviewU.S. FDA. Thymosin beta-4 fragment (LKKTETQ), also known as TB-500.
- Canadian public advisoryHealth Canada. Advisory on unauthorized injectable peptides, including TB-500. 2026.
Related products
Continue comparing.
Peptide · Vial
GHK-CU
From CA$54.9950mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Peptide · Pen
MOTS-c
From CA$6410mg20mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.